piperacillin and tazobactam and sodium chloride
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER (piperacillin and tazobactam and sodium chloride) by B. Braun is 12. Approved for older) for the treatment of appendicitis (complicated by rupture, abscess), peritonitis caused by beta-lactamase producing isolates of escherichia coli and 12 more indications. First approved in 2025.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
Piperacillin/tazobactam with sodium chloride in duplex container is a fixed-dose combination antibiotic administered intravenously for moderate-to-severe infections including nosocomial pneumonia, intra-abdominal infections, skin infections, and pelvic inflammatory disease. Piperacillin is a beta-lactam antibiotic while tazobactam is a beta-lactamase inhibitor that extends piperacillin's spectrum against resistant organisms. The combination achieves efficacy through time above minimum inhibitory concentration (MIC) against infecting pathogens.
Early-stage launch product with significant growth potential in hospital settings; commercial teams will focus on formulary conversion and penetration against established competitors.
12.1 Mechanism of Action Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is an antibacterial drug [see ]. 12.2 Pharmacodynamics The pharmacodynamic parameter for piperacillin and tazobactam that is most predictive of clinical and microbiological efficacy is time above MIC.…
Worked on PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moRoles on this launch team focus on securing hospital formulary positions, converting prescribers from ZOSYN and competitors, and educating pharmacy on duplex container benefits and cost-effectiveness. Career growth opportunities are moderate given the mature market and lack of clinical expansion pipeline; team size will be lean relative to peak-stage products.